<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aminolevulinic acid (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aminolevulinic acid (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aminolevulinic acid (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="113613" href="/d/html/113613.html" rel="external">see "Aminolevulinic acid (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52601666"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gleolan</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F55613293"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Gleolan</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50213753"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F50352172"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12ce2012-e953-4a34-91ef-9d721259c005">Glioma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glioma (optical imaging agent):</b>
<b>Oral:</b> 20 mg/kg administered 3 hours (range: 2 to 4 hours) prior to the start of anesthesia.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990385"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Clearance may be reduced in patients with renal impairment; approximately one-third of a dose is excreted unchanged in the urine, however, it is not known if dosage adjustment is necessary.</p></div>
<div class="block doha drugH1Div" id="F50987464"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Clearance may be reduced in patients with hepatic impairment, however, it is not known if dosage adjustment is necessary.</p></div>
<div class="block doe drugH1Div" id="F50352173"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F50274780"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Aphasia (8%), hemiparesis (8%), headache (3%), hemiplegia (2%), seizure (2%), hypoesthesia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase (grade ≥2: 8% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (&gt;1%), vomiting (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum ALT (grade ≥2: 3% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Monoplegia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Hemianopia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Ataxia</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, anaphylactic shock, angioedema, cerebral edema, chills, diarrhea, erythema, fixed drug eruption, metabolic acidosis, skin photosensitivity, solar dermatitis, urticaria</p></div>
<div class="block coi drugH1Div" id="F50193061"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to aminolevulinic acid or any component of the formulation; hypersensitivity to porphyrins; acute or chronic types of porphyria</p></div>
<div class="block war drugH1Div" id="F50352161"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including serious hypersensitivity) have occurred; these reactions include anaphylactic shock, swelling, and urticaria. Cardiopulmonary resuscitation personnel and equipment should be readily available. Monitor all patients for hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Reduce exposure to sunlight or room lights for 48 hours postoperatively. Due to the risk of phototoxic reactions, do not administer other phototoxic medications for 24 hours before and after systemic aminolevulinic acid administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Should only be used by neurosurgeons who have completed a training program on use of fluorescence in surgery. Aminolevulinic acid must be used with a standard surgical operating microscope adapted with a blue light emitting light source (power density 40 to 80 mW/cm<sup>2</sup>) and ancillary excitation and emission filters to visualize fluorescence excitation in the wavelength of 375 to 440 nm and for observation from 620 to 710 nm (filters transmit porphyrin fluorescence as red-violet, as well as a fraction of backscattered blue excitation light necessary for distinguishing nonfluorescing tissue).</p>
<p style="text-indent:-2em;margin-left:4em;">• Misinterpretation: Errors may occur with the use of systemic aminolevulinic acid for intraoperative visualization of malignant glioma (including false negatives and false positives)<i>. </i>Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma. Fluorescence may be observed in areas of inflammation or metastases due to other tumor types.</p></div>
<div class="block foc drugH1Div" id="F52601667"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gleolan: 1.5 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F52601665"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52777997"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Gleolan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.5 g (per each): $3,346.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55613294"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gleolan: 1.5 g (1 ea)</p></div>
<div class="block adm drugH1Div" id="F50352177"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For oral administration only. Must be reconstituted by a health care provider prior to administration (see Preparation for Administration). Administer 3 hours (range 2 to 4 hours) prior to the start of anesthesia.</p></div>
<div class="block use drugH1Div" id="F50193060"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Glioma (optical imaging agent):</b> Adjunct for visualization of malignant tissue during surgery in patients with glioma (suspected WHO grades III or IV on preoperative imaging)</p></div>
<div class="block mst drugH1Div" id="F50352156"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aminolevulinic acid (systemic) may be confused with aminolevulinic acid (topical), methyl aminolevulinate.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">For oral use only. Inadvertent intravenous injection could occur due to packaging in what looks like a parenteral vial (ISMP 2018).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F50305332"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F50305329"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Photosensitizing Agents: May enhance the photosensitizing effect of Aminolevulinic Acid (Systemic).<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F50352158"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F50352159"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if aminolevulinic acid (systemic) is present in breast milk. The manufacturer recommends breastfeeding women pump and discard breast milk for 24 hours (5 to 6 half-lives) after aminolevulinic acid (systemic) administration to decrease exposure to the breastfed infant.</p></div>
<div class="block mop drugH1Div" id="F50352179"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs/symptoms of hypersensitivity reactions.</p></div>
<div class="block pha drugH1Div" id="F50352165"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;">Aminolevulinic acid (ALA) occurs endogenously as a metabolite formed in the mitochondria from succinyl-CoA and glycine. Exogenous administration of systemic ALA leads to accumulation of the ALA metabolite, PpIX in tumor cells. During glioma surgery, systemic ALA is used in conjunction with an operating microscope adapted with a blue emitting light source (power density 40 to 80 mW/cm<sup>2</sup>) and filters for excitation light of wavelength 375 to 440 nm, and observation at wavelengths of 620 to 710 nm, allowing tumor tissue to be visualized as red fluorescence (tissue lacking sufficient PpIX concentrations appear blue).</p></div>
<div class="block phk drugH1Div" id="F50352166"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized to PpIX (actual fraction of administered aminolevulinic acid [ALA] that is metabolized to PpIX is unknown).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 100% (range: 78.5% to 131.2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Oral: ALA: 0.9 ± 1.2 hours (range: 0.8 to 1.3 hours); PpIX: 3.6 ± 1.8 hours (range: 1.2 to 7.8 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral: 0.8 hours (range: 0.5 to 1 hour); PpIX: 4 hours (range: 1.2 to 7.8 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (27% to 57%; as parent drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50351990"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Levulan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alabel | Alaglio</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Gleolan (aminolevulinic acid hydrochloride) [prescribing information]. Lexington, KY: NX Development Corp; March 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 113611 Version 49.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
